In any review of mifepristone, the FDA will now have to grapple with Judge Otake’s conclusion that the 2023 REMS decision for ...
Health Affairs' Rob Lott interviews Michael T. Osterholm, the director of the Center for Infectious Disease Research and ...
If we are serious about narrowing health gaps, then our environmental protections must be safeguarded against political ...
We must resist the temptation to reinterpret the Bayh-Dole Act even in an effort to improve the affordability of and access ...
Eli Sperling has traveled and conducted research extensively throughout the Middle East, spending significant time in Israel, Cairo and the Sinai Peninsula. He holds ...
Without policy intervention to address average sales price-based challenges to biosimilar market sustainability, there is a ...
There are three obstacles to faster development and deployment of non-addictive pain treatments. They are the business ...
US v. Skrmetti undermined constitutional guardrails that guarantee rigorous assessment of medical justifications for policies limiting the rights of transgender people and women, creating a need and ...
While recent fertility drug-related announcements by the Trump administration could result in savings for women—especially ...
The No Surprises Act has protected patients from surprise medical bills. However, the law’s incentives for insurers acting as ...
It is essential to weigh the report’s recommendations not only for their technical merit but also for their political ...
The North Carolina State Health Plan experience shows us that large, self-insured employers can work to bend the cost curve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback